SCICLONE PHARMACEUTICALS INC 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Jul 3, 2017
Insider Transaction Report
Form 4
Blobel Friedhelm
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2017-06-30$3.55/sh+27,654$98,172→ 149,863 total - Exercise/Conversion
Common Stock
2017-06-30$5.13/sh+7,390$37,911→ 129,599 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2017-06-30−27,654→ 0 totalExercise: $3.55Exp: 2020-03-05→ Common Stock (27,654 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2017-06-30−7,390→ 142,610 totalExercise: $5.13Exp: 2021-05-12→ Common Stock (7,390 underlying) - Sale
Common Stock
2017-06-30$11.00/sh−27,654$304,194→ 122,209 total - Sale
Common Stock
2017-06-30$11.00/sh−7,390$81,290→ 122,209 total
Footnotes (4)
- [F1]The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
- [F2]Granted under the Issuer's 2005 Equity Incentive Plan.
- [F3]25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
- [F4]25% of such shares vest April 5, 2012 and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.